Sanger Institute cancer researcher’s innovation recognised
Dr Mathew Garnett has received one of the first Excellence Awards given by the National Cancer Research Institute (NCRI). The Innovation Award highlights the work of Dr Garnett and his team in producing hundreds of patient-derived 3D organoid cultures as a community resource to accelerate cancer research.
The Garnett group at the Wellcome Sanger Institute have created hundreds of organoids – 3D clusters of cells derived from patients’ tumours that are grown in the laboratory to represent a patient’s cancer. Using these organoids, the team are investigating the genetic causes of several different types of cancer, including breast, oesophageal, colon and lung cancers.
Dr Garnett and his team are using these organoids* to investigate the susceptibility of various cancer subtypes to panels of different drugs. They aim to understand the genetic changes that make certain cancers respond to drugs and others not, and pin down genes that are essential for each cancer’s survival to serve as new drug targets.
Through the use of organoid technology, genome sequencing, gene knock-out experiments and drug testing, Dr Garnett and his team are identifying the weak spots of different cancers. As a result of this work, new guidelines for the future of precision cancer treatments will be created and shared in the form of the Cancer Dependency Map** - a detailed rulebook of precision cancer treatments to help more patients receive effective therapies.
To recognise the scientific advances made by Dr Garnett and his team, he was awarded an Innovation Award by the NCRI after being nominated by Dr Alexandra Bonner, Head of Research Resources at Breast Cancer Now.
“It is an enormous honour to receive the NCRI Innovation award on behalf of the dedicated team members involved in this research. The use of organoids has already begun to provide insights into the mechanisms underpinning the causes of cancer and how we might develop better treatments for patients.”
Dr Mathew Garnett, from the Wellcome Sanger Institute
The Awards have been created to celebrate the 15th year anniversary of the NCRI Cancer Conference and are directly linked to the key strategic objectives of the partnership, which aims to accelerate progress in cancer research through collaboration.
“We are delighted to recognise and honour the achievements made by these individuals and teams who have worked effortlessly in the community to help accelerate progress in cancer research for the benefit of patients and society.”
Dr Iain Frame, CEO of National Cancer Research Institute (NCRI)
The Awards will be presented on Monday 4th November at the NCRI Cancer Conference taking place in Glasgow at the Scottish Event Campus.